{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:02:28Z","timestamp":1787068948715,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81970162"],"award-info":[{"award-number":["No. 81970162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82070208"],"award-info":[{"award-number":["82070208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Translational Research Grant of NCRCH","award":["2020ZKZC02"],"award-info":[{"award-number":["2020ZKZC02"]}]},{"name":"Translational Research Grant of NCRCH","award":["2021WWB05"],"award-info":[{"award-number":["2021WWB05"]}]},{"name":"Natural Science Foundation of Chongqing Innovation Group Science Program","award":["cstc2021jcyj-cxttX0001"],"award-info":[{"award-number":["cstc2021jcyj-cxttX0001"]}]},{"name":"Chongqing Science and Health Joint Medical Research Major Project","award":["2022DBXM003"],"award-info":[{"award-number":["2022DBXM003"]}]},{"name":"Chongqing Science and Health Joint Medical Research Major Project","award":["2022ZDXM025"],"award-info":[{"award-number":["2022ZDXM025"]}]},{"name":"Military Clinical Medical Innovation Project of Xinqiao hospital","award":["2021JSLC0003"],"award-info":[{"award-number":["2021JSLC0003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The conditioning regimen is an important part of autologous hematopoietic stem cell transplantation (ASCT). We explored the efficacy and safety of an optimized BEAC (adjusted-dose, intermediate-dose cytarabine and reduced-dose cyclophosphamide, AD-BEAC) conditioning regimen for non-Hodgkin lymphoma (NHL). A total of 141 NHL patients received AD-BEAC or a standard-dose BEAC (SD-BEAC) conditioning regimen from January 2007 to December 2017, and 104 patients were included in the study after 1:1 propensity matching. The 5-year overall survival (OS) and progression free survival (PFS) rates were significantly higher with AD-BEAC than with SD-BEAC (82.7% vs. 67.3%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.039; 76.9% vs. 57.7%,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.039). Transplant-related mortality (TRM) was 3.8% in both the AD-BEAC and SD-BEAC groups. The AD-BEAC group had lower incidence of oral ulcers and cardiotoxicity than the SD-BEAC group. An optimized BEAC conditioning regimen is an effective conditioning regimen for ASCT in NHL with acceptable toxicity, that is more effective and safer than a standard BEAC conditioning regimen.\n                  <\/jats:p>","DOI":"10.1007\/s12185-024-03755-7","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T11:02:12Z","timestamp":1712574132000},"page":"96-105","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimized BEAC conditioning regimen improves clinical outcomes of autologous hematopoietic stem cell transplantation in non-Hodgkin lymphomas"],"prefix":"10.1007","volume":"120","author":[{"given":"Sha","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"3","key":"3755_CR1","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","volume":"12","author":"U Zahid","year":"2017","unstructured":"Zahid U, Akbar F, Amaraneni A, Husnain M, Onyee Chan O, Riaz IB, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12(3):217\u201326.","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"3755_CR2","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/sj.leu.2404850","volume":"21","author":"S Montoto","year":"2007","unstructured":"Montoto S, Canals C, Rohatiner AZ, Taghipour G, Sureda A, Schmitz N, et al. Long-term follow-up of high-dose treatment with autologous hematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia. 2007;21(11):2324\u201331.","journal-title":"Leukemia"},{"issue":"6","key":"3755_CR3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen YB, Lane AA, Logan B, Zhu XC, Akpek C, Aljurf M, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21(6):1046\u201353.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"3755_CR4","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1111\/ajco.12610","volume":"13","author":"Y Shi","year":"2017","unstructured":"Shi Y, Liu P, Zhou SY, Yang JL, Han XH, He XH, et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: efficacy and toxicity. Asia Pac J Clin Oncol. 2017;13(5):e423\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"1","key":"3755_CR5","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","volume":"71","author":"WS Velasquez","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71(1):117\u201322.","journal-title":"Blood"},{"issue":"1","key":"3755_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-008-0847-y","volume":"64","author":"SJ Sym","year":"2009","unstructured":"Sym SJ, Lee DH, Kang HJ, Nam SH, Kim HY, Kim SJ, et al. A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory\/relapsed aggressive non-Hodgkin\u2019s lymphoma. Cancer Chemother Pharmacol. 2009;64(1):27\u201333.","journal-title":"Cancer Chemother Pharmacol"},{"key":"3755_CR7","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1038\/sj.bmt.1705175","volume":"36","author":"T Kuittinen","year":"2005","unstructured":"Kuittinen T, Husso-Saastamoinen M, Sipola P, Vuolteenaho O, Ala-Kopsala M, Nousiainen T, et al. Very acute cardiac toxicity during BEAC chemotherapy in non Hodgkin\u2019s lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant. 2005;36:1077\u201382.","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"3755_CR8","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1182\/blood.V68.5.1114.1114","volume":"68","author":"MA Goldberg","year":"1986","unstructured":"Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68(5):1114\u20138.","journal-title":"Blood"},{"issue":"3","key":"3755_CR9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A, Jerkeman M, R\u00e4ty R, Andersen NS, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Hematol. 2012;158(3):355\u201362.","journal-title":"Br J Hematol"},{"key":"3755_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13045-015-0186-5","volume":"8","author":"L Gao","year":"2015","unstructured":"Gao L, Zhang C, Liu Y, Liu Y, Su Y, Wang SB, et al. Favorable outcome of haploidentical hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia: a multicenter study in Southwest China. J Hematol Oncol. 2015;8:90.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"3755_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3324\/haematol.2019.226985","volume":"106","author":"Y Liu","year":"2021","unstructured":"Liu Y, Rao J, Li J, Wen Q, Wang SB, Lou SF, et al. Tandem autologous hematopoietic stem cell transplantation for treatment of adult T-cell lymphoblastic lymphoma: a multiple center prospective study in China. Hematologica. 2021;106(1):163\u201372.","journal-title":"Hematologica"},{"issue":"5","key":"3755_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579\u201386.","journal-title":"J Clin Oncol"},{"key":"3755_CR13","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1182\/blood-2011-08-372508","volume":"118","author":"H Liu","year":"2011","unstructured":"Liu H, Rich ES, Godley L, Odenike O, Joseph L, Marino S, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118:6438\u201345.","journal-title":"Blood"},{"issue":"2","key":"3755_CR14","doi-asserted-by":"publisher","first-page":"5812","DOI":"10.4081\/hr.2015.5812","volume":"7","author":"H Kaneko","year":"2015","unstructured":"Kaneko H, Tsutsumi Y, Fujino T, Kuwahara S, Ohshiro M, Iwai T, et al. Favorable event free-survival of high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation for higher risk diffuse large B-cell lymphoma in first complete remission. Hematol Rep. 2015;7(2):5812.","journal-title":"Hematol Rep"},{"issue":"22","key":"3755_CR15","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/blood.V114.22.880.880","volume":"114","author":"E Hoster","year":"2009","unstructured":"Hoster E, Metzner B, Forstpointner R, Pfreundschuh M, Tr\u00fcmper L, Hallek M, et al. Autologous stem cell transplantation and addition of rituximab independently prolong response duration in advanced stage mantle cell lymphoma. Blood. 2009;114(22):362\u20133.","journal-title":"Blood"},{"issue":"9","key":"3755_CR16","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1038\/leu.2014.79","volume":"28","author":"P Corradini","year":"2014","unstructured":"Corradini P, Vitolo U, Rambaldi A, Miceli R, Patriarca F, Gallamini A, et al. Intensified chemoimmunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. Leukemia. 2014;28(9):1885\u201391.","journal-title":"Leukemia"},{"issue":"3","key":"3755_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11596-021-2394-2","volume":"41","author":"Q Wen","year":"2021","unstructured":"Wen Q, Gao L, Xiong JK, Li Q, Wang SB, Wang JS, et al. High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation as frontline therapy for intermediate\/high-risk diffuse large B-Cell lymphoma. Curr Med Sci. 2021;41(3):465\u201373.","journal-title":"Curr Med Sci"},{"issue":"7","key":"3755_CR18","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/sj.bmt.1703888","volume":"31","author":"O Paltiel","year":"2003","unstructured":"Paltiel O, Rubinstein C, Or R, Gordon L, Deutsch L, Polliack A, et al. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma. Bone Marrow Transplan. 2003;31(7):565\u20139.","journal-title":"Bone Marrow Transplan"},{"issue":"4","key":"3755_CR19","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00277-020-03942-6","volume":"99","author":"DY Kim","year":"2020","unstructured":"Kim DY, Chung JS, Jo JC, Cho SH, Shin HJ. Phase II study of safety and efficacy of BEB (bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma. Ann Hematol. 2020;99(4):819-828.21.","journal-title":"Ann Hematol"},{"issue":"7","key":"3755_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00277-004-1003-3","volume":"84","author":"D Nachbaur","year":"2005","unstructured":"Nachbaur D, Greinix HT, Koller E, Krieger O, Linkesch W, Kasparu H, et al. Long-term results of autologous stem cell transplantation for Hodgkin\u2019s disease (HD) and low-\/intermediate-grade B non-Hodgkin\u2019s lymphoma (NHL): a report from the Austrian Stem Cell Transplantation Registry (ASCTR). Ann Hematol. 2005;84(7):462\u201373. https:\/\/doi.org\/10.1007\/s00277-004-1003-3.","journal-title":"Ann Hematol"},{"issue":"1","key":"3755_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","volume":"87","author":"JC Jo","year":"2008","unstructured":"Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008;87(1):43\u20138.","journal-title":"Ann Hematol"},{"issue":"7","key":"3755_CR22","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.bbmt.2016.03.018","volume":"22","author":"CR Flowers","year":"2016","unstructured":"Flowers CR, Costa LJ, Pasquini MC, Le-Rademacher J, Lill M, Shore TB, et al. Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes. Biol Blood Marrow Transplant. 2016;22(7):1197\u2013205.","journal-title":"Biol Blood Marrow Transplant"},{"key":"3755_CR23","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.1999.17.8.2446","volume":"17","author":"AP Rapoport","year":"1999","unstructured":"Rapoport AP, Miller Watelet LF, Linder T, Eberly S, Raubertas RF, Lipp J, et al. Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Oncol. 1999;17:2446\u201353.","journal-title":"J Clin Oncol"},{"issue":"3","key":"3755_CR24","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1365-2141.2006.06323.x","volume":"135","author":"SR Fanning","year":"2006","unstructured":"Fanning SR, Rybicki L, Kalaycio M, Andresen S, Kuczkowski E, Pohlman B, et al. Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Hematol. 2006;135(3):374\u201381.","journal-title":"Br J Hematol"},{"issue":"4","key":"3755_CR25","doi-asserted-by":"publisher","first-page":"e13302","DOI":"10.1111\/tid.13302","volume":"22","author":"JR Garz\u00f3n Herazo","year":"2020","unstructured":"Garz\u00f3n Herazo JR, Mu\u00f1oz Velandia OM, Solano JC, Pimienta LM, Lemus WJF. The nutrition risk index is associated with bacteremia within 30 days after autologous stem cell transplantation in patients with multiple myeloma. Transpl Infect Dis. 2020;22(4):e13302.","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"3755_CR26","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00277-013-1872-4","volume":"93","author":"JL Pi\u00f1ana","year":"2014","unstructured":"Pi\u00f1ana JL, Montesinos P, Martino R, Vazquez L, Rovira M, L\u00f3pez J, et al. Incidence, risk factors, and outcome of bacteremia following autologous hematopoietic stem cell transplantation in 720 adult patients. Ann Hematol. 2014;93(2):299\u2013307.","journal-title":"Ann Hematol"},{"key":"3755_CR27","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1182\/asheducation-2011.1.498","volume":"2011","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW. Relapsed\/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Progra. 2011;2011:498\u2013505.","journal-title":"Hematology Am Soc Hematol Educ Progra"},{"issue":"12","key":"3755_CR28","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/ijc.33761","volume":"149","author":"J Ji","year":"2021","unstructured":"Ji J, Liu Z, Kuang P, Dong T, Chen XC, Li J, et al. A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed\/refractory non-Hodgkin\u2019s lymphomas. Int J Cancer. 2021;149(12):2075\u201382.","journal-title":"Int J Cancer"},{"key":"3755_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.681984","author":"F Marofi","year":"2021","unstructured":"Marofi F, Rahman HS, Achmad MH, Sergeevna KN, Suksatan W, Abdelbasset WK, et al. A deep insight into CAR-T-Cell therapy in non-Hodgkin lymphoma: application, opportunities, and future directions. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.681984.","journal-title":"Front Immunol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03755-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-024-03755-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-024-03755-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:17:54Z","timestamp":1720138674000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-024-03755-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["3755"],"URL":"https:\/\/doi.org\/10.1007\/s12185-024-03755-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}